Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Alpha-emitting radiopharmaceuticals

8 evidence topics · 4 sources

Symptomatic bone-metastatic disease: overall survival versus placebo
AnalysisRadium Ra 223 dichloride, median months (95% CI)Placebo, median months (95% CI)Hazard ratio (95% CI)
Interim analysis“14.0 (12.1, 15.8)”“11.2 (9.0, 13.2)”“0.695 (0.552, 0.875)”
Updated analysis“14.9 (13.9, 16.1)”“11.3 (10.4, 12.8)”“0.695 (0.581, 0.832)”